Please provide your email address to receive an email when new articles are posted on . ORLANDO — In this video, Matthew S. Davids, MD, said data from the BRUIN-313 trial supports front-line approval ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. With CLL, we know there is a component of T ...

The discussion will cover fixed-duration treatments vs continuous therapy for CLL and provide a brief overview of venetoclax-based regimens approved for 12 cycles with obinutuzumab and 24 cycles with ...

This study provides a comprehensive review of both established and emerging prognostic markers in chronic lymphocytic leukemia (CLL), and their role in predicting disease, treatment response, and ...

Ibrutinib is effective for R/R CLL, with a median follow-up of 42.2 months, confirming its role in prolonged disease control. Factors like older age, previous therapies, and double-hit TP53 ...

Chronic lymphocytic leukemia (CLL) treatment options depend on your diagnosis. In earlier stages, “watchful waiting” may be recommended. More advanced CLL may require a combination of therapies.

B-cell chronic lymphocytic leukemia (CLL) occurs when abnormal B cells accumulate in the bone marrow and blood. This crowds out healthy blood cells and weakens the body’s ability to fight infections.